Theravance Biopharma, Inc. TBPH

Latest FY: 2025 Healthcare Biotechnology
Market Price $17.02
Market Cap $877.43M
P/E Ratio 8.26
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑66.9% YoY
$107.46M
3-Yr CAGR: 27.9%
Net Income ↑287.7% YoY
$105.89M
Net Margin: 98.5%
Free Cash Flow ↑2,109.8% YoY
$238.50M
FCF Yield: 27.18%
EPS (Diluted) ↑279.1% YoY
$2.06
Basic: $2.10
Return on Equity Efficiency
35.7%
ROA: 21.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (TBPH)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $48.6M $45.8M $-190.7M 0.00% $-99.0M $-101.1M
FY 2017 $15.4M -68.4% $9.4M $-285.4M -49.7% 0.00% $-201.1M $-203.5M -101.2%
FY 2018 $60.4M +292.4% $-141.7M $-215.5M +24.5% 0.00% $-112.9M $-120.1M +41.0%
FY 2019 $73.4M +21.6% $-145.8M $-236.5M -9.7% 0.00% $-238.2M $-241.4M -101.0%
FY 2020 $71.9M -2.1% $-189.1M $-278.0M -17.6% 0.00% $-250.4M $-257.0M -6.5%
FY 2021 $55.3M -23.0% $-158.5M $-199.4M +28.3% $-2.87 0.00% $-207.9M $-211.3M +17.8%
FY 2022 $51.3M -7.2% $-24.9M $872.1M +537.3% $11.85 +512.9% 0.00% $-187.0M $-187.6M +11.2%
FY 2023 $57.4M +11.8% $14.1M $-55.2M -106.3% $-1.00 -108.4% 0.00% $-27.0M $-29.5M +84.3%
FY 2024 $64.4M +12.1% $22.2M $-56.4M -2.2% $-1.15 -15.0% 0.00% $-11.5M $-11.9M +59.8%
FY 2025 $107.5M +66.9% $70.0M $105.9M +287.7% $2.06 +279.1% 0.00% $238.5M $238.5M +2,109.8%
$

Valuation

Market Price $17.02
Market Cap $877.43M
Enterprise Value $709.63M
P/E Ratio 8.26
P/B Ratio 2.96
FCF Yield 27.18%
Dividend Yield N/A
Shares Outstanding 51,553,000
%

Profitability & Margins

Gross Margin 65.18%
Operating Margin 3.35%
Net Margin 98.54%
Return on Equity (ROE) 35.69%
Return on Assets (ROA) 21.81%
Asset Turnover 0.22x
Revenue 3-Yr CAGR 27.91%
🛡️

Financial Health & Liquidity

Current Ratio 10.93
Cash Ratio 4.38
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $167.81M
Total Debt N/A
Book Value / Share $5.76
💧

Cash Flow Efficiency

Operating Cash Flow $238.54M
Capital Expenditures (CapEx) $42.00K
Free Cash Flow $238.50M
OCF / Revenue 221.97%
FCF / Revenue 221.93%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.06
EPS (Basic) $2.10
Dividends / Share N/A
Book Value / Share $5.76
EPS YoY Growth 279.13%
🏛️

Balance Sheet (FY 2025)

Total Assets $485.57M
Total Liabilities $188.85M
Stockholders' Equity $296.72M
Current Assets $418.46M
Current Liabilities $38.30M